<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>生物制药小编 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-05T07:42:09+08:00</updated>
  <subtitle>“新起点，再出发”——生物医药小编与您共同关注生物制药行业热点。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>Tubulis的ADC组合快速筛选技术</title>
    <updated>2021-01-04T16:19:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/SBthlDWQ6s-Z1bl6SMo4FQ</id>
    <link href="https://mp.weixin.qq.com/s/SBthlDWQ6s-Z1bl6SMo4FQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>基于共刺激分子4-1BB的双特异性抗体</title>
    <updated>2021-01-03T09:16:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/HDbUF86ooJVeOMH79kuu4g</id>
    <link href="https://mp.weixin.qq.com/s/HDbUF86ooJVeOMH79kuu4g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>TILs-TCR工程改造技术要点</title>
    <updated>2021-01-02T16:48:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-02:/s/063DORva7l4Z-RC5MtfCAA</id>
    <link href="https://mp.weixin.qq.com/s/063DORva7l4Z-RC5MtfCAA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>简评靶向GPCR的临床在研抗体</title>
    <updated>2021-01-01T19:37:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-01:/s/A-r-ofBdVdd-kCRBlYL4hA</id>
    <link href="https://mp.weixin.qq.com/s/A-r-ofBdVdd-kCRBlYL4hA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>基于PD-1/L1的双特异抗体突破在何方？</title>
    <updated>2020-12-31T16:47:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-31:/s/wLmY9E455wrSVsSMDOkAwQ</id>
    <link href="https://mp.weixin.qq.com/s/wLmY9E455wrSVsSMDOkAwQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体药物今年延续强势</title>
    <updated>2020-12-30T14:35:31+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-30:/s/Q5I93s-fDlABJ8ue0L8zWQ</id>
    <link href="https://mp.weixin.qq.com/s/Q5I93s-fDlABJ8ue0L8zWQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>三大抗体工程技术改善抗体药代动力学特性</title>
    <updated>2020-12-29T16:57:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-29:/s/GBkoBwsGpgxjxS5Ew0Mx9Q</id>
    <link href="https://mp.weixin.qq.com/s/GBkoBwsGpgxjxS5Ew0Mx9Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百抗大战</title>
    <updated>2020-12-29T16:57:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-29:/s/3Rjjvp_C8aVqiP5m5HHL2g</id>
    <link href="https://mp.weixin.qq.com/s/3Rjjvp_C8aVqiP5m5HHL2g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>瑞博生物启动首个小核酸药物的临床研究：乙肝药物RB1016</title>
    <updated>2020-12-29T08:54:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-29:/s/80PWcoaBcwVCU30z7KckKg</id>
    <link href="https://mp.weixin.qq.com/s/80PWcoaBcwVCU30z7KckKg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>正式启动！2021年不可多得的细胞基因免疫治疗技术专场盛会有哪些精彩看点？</title>
    <updated>2020-12-29T08:54:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-29:/s/MKnytH6QAKPm5pTBgnWJzA</id>
    <link href="https://mp.weixin.qq.com/s/MKnytH6QAKPm5pTBgnWJzA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>影响抗体药物ADA（Anti-Drug antibody）产生的因素</title>
    <updated>2020-12-28T09:18:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-28:/s/VZidrEghK9gCUusOKK1K4g</id>
    <link href="https://mp.weixin.qq.com/s/VZidrEghK9gCUusOKK1K4g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>正式启动！2021年不可多得的细胞基因免疫治疗技术专场盛会有哪些精彩看点？</title>
    <updated>2020-12-28T09:18:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-28:/s/TvagRNonLf8St4xmGWYnGA</id>
    <link href="https://mp.weixin.qq.com/s/TvagRNonLf8St4xmGWYnGA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>甘李药业研发CD19/CD22双特异性CAR-T疗法</title>
    <updated>2020-12-26T21:54:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-26:/s/dAPu4XVVxvH9K94i9iKGGQ</id>
    <link href="https://mp.weixin.qq.com/s/dAPu4XVVxvH9K94i9iKGGQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>正式启动！2021年不可多得的细胞基因免疫治疗技术专场盛会有哪些精彩看点？</title>
    <updated>2020-12-26T21:54:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-26:/s/dmUpV0Olx342nhLbvg9fKg</id>
    <link href="https://mp.weixin.qq.com/s/dmUpV0Olx342nhLbvg9fKg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>